Churchill Capital Corp Xi (CCXI) Stock Price & Analysis
Churchill Capital Corp Xi (CCXI) rose 0.00% to USD 10.29 as of June 10, 2026 at 07:38 UTC, according to Nexqual real-time market data.
CCXI last closed at USD 10.29; the session ranged USD 10.29–10.29 on volume of 17 shares. Market capitalization is $573.15M, with a 52-week range of USD 10.07–11 (NGM). Source: Nexqual, June 10, 2026 at 07:38 UTC.
Key Statistics (as of June 10, 2026 at 07:38 UTC)
| Price | USD 10.29 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 10.29 |
| Open | USD 10.29 |
| Day Range | USD 10.29 – 10.29 |
| 52-Week Range | USD 10.07 – 11 |
| Volume | 17 shares |
| Market Cap | $573.15M |
| Exchange | NGM |
Technical Analysis (CCXI)
Nexqual's technical model rates CCXI "BUY" based on 5 bullish and 1 bearish signals across 83 daily candles, as of June 10, 2026 at 07:38 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 58.07 (neutral) |
| vs SMA50 | Above (USD 10.22) |
| MACD | 0.01 (positive) |
Analyst Ratings (CCXI)
Wall Street analysts rate CCXI "None", per Nexqual as of June 10, 2026 at 07:38 UTC.
| Consensus Rating | None |
|---|
Earnings (CCXI)
Source: Nexqual, June 10, 2026 at 07:38 UTC.
Financials & Fundamentals (CCXI)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 8.13 |
| Total Cash | $410,097 |
| Total Debt | $0 |
Source: Nexqual, June 10, 2026 at 07:38 UTC.
Financial Health Score (CCXI)
Nexqual rates Churchill Capital Corp Xi's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 07:38 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Mixed — $410K cash, no debt |
| Cash Flow | Weak — Operating cash flow -$1M |
| Efficiency | Mixed — No data |
Ownership (CCXI)
| Insider Ownership | +1.19% |
|---|---|
| Institutional Ownership | +76.28% |
| Shares Outstanding | 41.90M |
| Float | 41.40M |
| Short % of Float | +0.01% |
Source: Nexqual, June 10, 2026 at 07:38 UTC.
Leadership (CCXI)
Churchill Capital Corp Xi is led by Michael S. Klein (age 61), Founder, CEO, President & Chairman of the Board, per Nexqual as of June 10, 2026 at 07:38 UTC.
| Founder, CEO, President & Chairman of the Board | Michael S. Klein (age 61) |
|---|---|
| Chief Financial Officer | Lee Jay Taragin (age 59) |
Major Backers & Investors (CCXI)
Notable institutional backers of Churchill Capital Corp Xi include Magnetar Financial LLC, Adage Capital Partners GP L.L.C., Fort Baker Capital Management LP, according to Nexqual as of June 10, 2026 at 07:38 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Magnetar Financial LLC | 6.44% |
| Adage Capital Partners GP L.L.C. | 6.44% |
| Fort Baker Capital Management LP | 6.01% |
| Polar Asset Management Partners Inc. | 4.77% |
| Sculptor Capital LP | 4.77% |
| Alberta Investment Management Corp | 3.58% |
| Shaw D.E. & Co., Inc. | 3.1% |
| Linden Advisors LP | 2.39% |
Source: Nexqual, June 10, 2026 at 07:38 UTC.
From Churchill Capital Corp Xi's Latest SEC 10-K Filing (filed 2026-03-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Our competitive strengths include the following:           Investment Criteria   We have developed the following high-level, non-exclusive investment criteria that we use to screen for and evaluate target businesses.
- Because we are able to complete our Business Combination using our cash, debt or equity securities, or a combination of the foregoing, we have the flexibility to use the most efficient combination that will allow us to tailor the consideration to be paid to the target business to fit its needs and desires.
Partnerships
- The Public Units were sold at a price of $10.00 per Public Unit, generating gross proceeds to our Company of $414,000,000.   Simultaneously with the closing of the Initial Public Offering and pursuant to the Private Placement Units Purchase Agreement, we completed the private sale of 500,000 Private Placement Units to our Sponsor in the Private Placement at a purchase price of $10.00 per Private Placement Unit, generating gross proceeds to our Company of $5,000,000.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KYNB | Kyntra Bio, Inc. | USD 6.69 | ▼ 0.3% |
| KPTI | Karyopharm Therapeutics Inc. | USD 8.69 | ▼ 4.3% |
| PTGX | Protagonist Therapeutics, Inc. | USD 105.87 | ▲ 8.72% |
| MGNX | MacroGenics, Inc. | USD 3.91 | ▲ 0% |
| PTCT | PTC Therapeutics, Inc. | USD 73.68 | ▲ 3.82% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:38 UTC. This page is informational and not investment advice.